Anil Singhvi (Managing Editor of Zee Business) shared his insights on a selection of stocks with a bullish surge in Sensex and Nifty50. His analysis covered several prominent companies, offering guidance on investment strategies and future prospects.
Singhvi began by focusing on Aurobindo Pharma, a stock that has garnered significant attention due to its strong operational performance in the March quarter. He advised investors to buy Aurobindo Pharma futures, setting targets at Rs 1,247, Rs 1,260, and Rs 1,275 with a stop loss at Rs 1,217. This recommendation comes on the back of the company’s growth across various segments, marking a second consecutive quarter of impressive performance.
Turning to United Spirits, Singhvi described the company’s recent results as a mixed bag. He suggested that investors wait for the management’s commentary, scheduled for later in the day, before making any decisions. This cautious approach reflects the need for further clarity on the company’s future outlook.
The performance of NTPC was also deemed a mixed bag by Singhvi. He anticipates some weakness in NTPC shares and recommends buying at lower levels, suggesting a strategic approach to capitalizing on potential dips.
Hindalco Industries emerged as a strong performer with a 32% year-on-year increase in consolidated net profit to Rs 3,174 crore for the March quarter. The company’s EBITDA also grew by about 25% to Rs 6,682 crore, with margins improving by 250 basis points to 12%. Brokerage firm Jefferies maintained its ‘buy’ call on Hindalco, raising its target price by Rs 15 to Rs 825. Singhvi echoed this sentiment, highlighting the company’s impressive financial results and positive market outlook.
Glenmark Pharma, on the other hand, presented a less favorable scenario, with results falling short of analysts’ expectations across the board. Despite this, Singhvi noted the strength in the company’s margins and EBITDA, suggesting that a 3-5% dip could present a good buying opportunity for investors.
Singhvi’s recommendations also included Hindustan Copper, a company that has demonstrated strong financial performance with its margin hitting the highest level in 11 quarters. He advised buying Hindustan Copper shares in the spot market, setting targets at Rs 377, Rs 382, and Rs 388 with a stop loss at Rs 365.
Cochin Shipyard received a bullish recommendation as well, following an exceptional quarterly performance. The company reported a 660% jump in net profit and a 100% increase in revenue. Despite the stock’s impressive rally—up 35% in five days and 120% in three months—Singhvi suggested buying Cochin Shipyard shares with targets of Rs 1,950, Rs 1,990, and Rs 2,025, and a stop loss at Rs 1,900.
Torrent Pharma was another stock on Singhvi’s radar, with a recommendation to buy futures for targets of Rs 2,675, Rs 2,695, and Rs 2,740, maintaining a stop loss at Rs 2,595. He noted the company’s improvement in operational performance and a strong future outlook.
Singhvi recommended buying Divi’s Labs futures, citing the company’s strong financial performance after several quarters of underwhelming results. He set targets at Rs 4,185, Rs 4,225, and Rs 4,290, with a stop loss at Rs 4,110.
